Capri Holdings Ltd vs Davita Inc — how do they compare? Capri Holdings Ltd trades at $15.62 (market cap $1.75B), while Davita Inc trades at $178.35 (market cap $11.72B). The key difference: Davita Inc is far larger — about 6.7× Capri Holdings Ltd's market cap, and Davita Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | DVA | |
|---|---|---|
Market Cap | $1.75B | $11.72B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $240.96 |
52-Week Low | $14.98 | $103.87 |
Enterprise Value | $3.03B | $24.44B |
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $15.295, up 2.1% today but near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with moving averages indicating selling pressure, while fundamentals reveal mixed performance - strong gross margins of 62.71% but recent net losses and declining revenue. Recent Q1 2027 earnings beat expectations despite revenue challenges, with the company revising full-year guidance downward due to Michael Kors inventory delays and softer luxury demand.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with Wall Street maintaining a cautious stance (44% buy ratings) despite a $19.60 consensus target representing 28% upside. Key risks include ongoing revenue declines, luxury market volatility, and execution challenges in revitalizing the Michael Kors brand amid competitive pressures.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Trailing returns across standard periods
Latest headlines on both assets
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →